First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
Pembrolizumab monotherapy has become the preferred treatment for patients with advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of at least 50%. However, little is known about the value of adding chemotherapy to pembrolizumab in...
Main Author: | Zuan Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-03-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/7/1/120.full |
Similar Items
-
A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non‐small cell lung cancer
by: Taisuke Isono, et al.
Published: (2021-05-01) -
Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer
by: Yixin Zhou, et al.
Published: (2020-03-01) -
Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
by: Ning Wan, et al.
Published: (2020-03-01) -
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
by: Weinberg F, et al.
Published: (2019-06-01) -
Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
by: Ya Chen, et al.
Published: (2021-04-01)